Search

Argenx SE

Ouvert

SecteurSoins de santé

810.2 0.8

Résumé

Variation du prix de l'action

24h

Actuel

Min

797

Max

820.2

Chiffres clés

By Trading Economics

Revenu

-315M

506M

Ventes

-1B

1.7B

P/E

Moyenne du Secteur

31.356

50.373

BPA

7.8

Marge bénéficiaire

29.402

Employés

1,863

EBITDA

-307M

539M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

-2.07% downside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

830M

49B

Ouverture précédente

809.4

Clôture précédente

810.2

Argenx SE Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 oct. 2026, 23:56 UTC

News
Correlated Moves

Jack Henry & Associates reported $17.9 million in deconversion revenue for Q1 2026 and projected $30 million for fiscal 2027.

29 oct. 2026, 23:56 UTC

News

Citigroup maintains Buy rating on Sherwin-Williams, lowering price target to $370; RBC Capital reaffirms Outperform rating, adjusting target to $383.

29 oct. 2026, 23:56 UTC

News

Duolingo faces multiple class action lawsuits alleging securities law violations related to false statements on user growth and AI content quality.

29 oct. 2026, 23:51 UTC

News

Argus Research downgraded Wendy's Co to Sell, citing concerns over growth prospects and competitive pressures in the fast-food sector.

29 oct. 2026, 23:51 UTC

News

Citigroup maintains Neutral rating on Rexford Industrial Realty, lowering its price target to $40 in a report published after market hours.

29 oct. 2026, 23:51 UTC

Social Media
News

MGM Resorts' shares declined after Macquarie lowered its price target to $46 and JP Morgan reduced its target to $39 following market close.

29 oct. 2026, 23:51 UTC

Macro Event
News

The European Central Bank held interest rates steady at 2.65% in October, aligning with market expectations amid rising inflation concerns.

29 oct. 2026, 23:46 UTC

News

JP Morgan maintains Overweight rating on C.H. Robinson Worldwide but lowers price target to $174, contributing to a modest decline in after-market trading.

29 oct. 2026, 23:46 UTC

News

Tenable Holdings, Inc. shares advanced in after-market trading as JP Morgan raised its price target to $41 and Canaccord Genuity increased its target to $54.

29 oct. 2026, 23:41 UTC

News
Correlated Moves

RBC Capital raised its price target on Prosperity Bancshares to $79, maintaining a Sector Perform rating in a report published after the market closed.

29 oct. 2026, 23:41 UTC

News

Olin Corporation reports Q3 net income of $14.4 million and projects Q4 adjusted EBITDA of $80 million to $100 million, citing customer destocking.

29 oct. 2026, 23:41 UTC

News

Prospect Capital Corporation prices a $300 million offering of 8.95% unsecured notes due in 2031, aimed at refinancing debt and general corporate purposes.

29 oct. 2026, 23:36 UTC

News

The Nikkei 225 Index declined in after-market hours following a drop in Japan's consumer confidence index to 35.0 and Toyota's production cuts in China.

29 oct. 2026, 23:31 UTC

News

The euro is gaining against the Norwegian krone as the ECB holds rates steady and warns of rising inflation risks, ending a six-day decline.

29 oct. 2026, 23:31 UTC

News

Lennar Corporation filed with the SEC to amend its revolving credit agreement, increasing commitments to $3.80 billion and borrowing capacity to $4.55 billion.

29 oct. 2026, 23:26 UTC

News

Macquarie maintains Neutral rating on Hilton Worldwide and raises price target to $333, reflecting a positive assessment of the company's performance and market position.

29 oct. 2026, 23:21 UTC

News

JP Morgan maintains Overweight rating on International Paper, lowering price target to $51, reflecting confidence amid a rise in the Paper & Plastic Packaging sector.

29 oct. 2026, 23:16 UTC

News

Exelixis reports Q3 2026 revenues of $658.7 million and GAAP net income of $218.1 million, exceeding analyst expectations, while shares declined in after-market trading.

29 oct. 2026, 23:16 UTC

News

PG&E Corp shares rose in after-market hours, supported by mixed options sentiment with a put/call ratio of 0.16 and decreased implied volatility at 41.1.

29 oct. 2026, 23:16 UTC

News
Correlated Moves

Brown & Brown Inc recognized as a Certified™ Great Place to Work® for the eighth year and included in Fortune's 2026 Best Workplaces lists.

29 oct. 2026, 23:12 UTC

News
Correlated Moves

SkyWest, Inc. reported Q3 2026 net income of $119.5 million, or $3.08 per share, with revenue of $1.12 billion, missing analyst expectations.

29 oct. 2026, 23:11 UTC

News

New Fortress Energy Inc. leases ten mobile turbines for up to 300 megawatts to a U.S. investment-grade company, enhancing earnings and liquidity.

29 oct. 2026, 23:11 UTC

News

Cherry Hill Mortgage Investment Corporation reported Q3 adjusted EPS of $0.14, revenues of $6.558 million, and a net loss of $1.5 million.

29 oct. 2026, 23:11 UTC

News

Ethereum is trading lower, reflecting a significant decline since Wednesday's close, amid cautious investor sentiment following the Fed's rate decision and falling crude oil prices.

29 oct. 2026, 23:06 UTC

News

Textron Inc reported Q3 revenue of $3.75 billion and raised 2026 GAAP EPS guidance to $5.64-$5.74, with shares advancing in after-market trading.

29 oct. 2026, 23:06 UTC

News

JP Morgan maintains Neutral rating on Centene Corp and raises price target to $75 in a report published today.

29 oct. 2026, 23:06 UTC

News

Biogen Inc. receives an upgrade to Buy from Argus Research with a price target of $280, while Canaccord Genuity raises its target to $272.

29 oct. 2026, 23:06 UTC

News

Ethereum is trading lower, continuing its decline as cautious investor sentiment grows following the Federal Reserve's rate decision and mixed economic signals.

29 oct. 2026, 23:06 UTC

News

Bitcoin faces downward pressure amid reports of a potential $2 billion hack linked to Binance, contributing to negative market sentiment and testing local range lows.

29 oct. 2026, 23:06 UTC

News

Bitcoin is under downward pressure amid reports of a potential $2 billion hack linked to Binance, testing local range lows as negative sentiment persists.

Comparaison

Variation de prix

Argenx SE prévision

Objectif de Prix

By TipRanks

-2.07% baisse

Prévisions sur 12 Mois

Moyen 438.33 EUR  -2.07%

Haut 545 EUR

Bas 223 EUR

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

6 ratings

5

Achat

0

Maintien

1

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
help-icon Live chat